ETDT 5 and Transmit 6 programmes. From the single marker association analysis, there was no evidence of association of NRG1 with BPAD in our sample (Table 1) . D8S1810 did exhibit a significant over transmission of allele 5 to bipolar probands (uncorrected P = 0.04) but the global P-value for this marker was not significant (Table 1 : P = 0.212). Interestingly, this marker was selected based on its presence within an Irish schizophrenia-associated haplotype, HapB IRE . 7 A range of two to three marker haplotypes, including HAP ICE and HapB IRE , also failed to exhibit any evidence of association with BPAD (Table 1) . A haplotype comprised of alleles from the three microsatellite markers (M3-M4-M5) did exhibit a marginal association (Table 1 , haplotype 1, 3, 5, uncorrected P = 0.04) which was not significant at the global haplotype level (Table 1 : P = 0.31). We hypothesized that if NRG1 is principally a gene for schizophrenia, a stratified analysis restricted to trios with probands that have experienced at least one psychotic episode may reveal an association with BPAD, similar to the findings of Green et al. 3 However, restriction of the association analysis to the subset of 59 trios with psychosis did not reveal any evidence for association of NRG1 with BPAD (data not shown).
To conclude, we have failed to replicate the findings of Green et al.
3 in a family-based collection which is not subject to the population substructure effects of casecontrol association studies. These findings suggest that NRG1 is not a susceptibility gene for BPAD in the Irish population. Interestingly, despite a plethora of positive associations of NRG1 with schizophrenia in diverse populations, the two Irish schizophrenia investigations have also been negative. 8, 9 Although a two-marker NRG1 haplotype (HapB IRE ) was initially reported to be associated with schizophrenia in an Irish case-control sample, 7 the association was no longer evident after further investigation within an extended sample. 9 We cannot rule out the possibility that our collection had insufficient power to replicate the association of NRG1 with BPAD. Indeed, there are moderate differences in the allele frequencies for SNPs surrounding the core haplotype in European populations, which would impact the power of replication studies, particularly for rarer alleles/haplotypes. 10 However, geographical variation is unlikely to be an issue in this case as the estimated frequency of the core haplotype in our samples (7.7%) was very similar to that reported by Green et al.
3 (7.8% in controls). To elucidate whether NRG1 is truly a susceptibility gene for BPAD, additional studies in family-based collections are required. The short allele of the serotonin transporter polymorphism (5HTTLPR) has been linked to psychiatric disorders, including depression or anxiety. Our analyses concerning the impact of 5HTTLPR on lateonset depression in a large community-based agecohort unexpectedly detected that 5HTTLPR strongly influences low-density lipoprotein (LDL)-cholesterol levels.
The serotonin transporter (SERT) regulates the serotonergic system via modulation of extracellular fluid serotonin concentrations. Transcriptional activity of human SERT is modulated by a repetitive element of varying length, in the 5 0 flanking region located B1.4 kb from the transcription start site, termed the serotonin transporter gene-linked polymorphic region (5HTTLPR). 5HTTLPR alleles are most commonly composed of either 14 ('short' allele S) or 16 ('long' allele L) repeated elements. The 5HTTLPR genotype distribution in a Caucasian population is 32% LL, 49% LS and 19% SS. 1 The serotonin transporter may contribute to several disorders and most reports comprise neuropsychiatric phenotypes such as anxiety disorders, depression and bipolar disorder linked to the S allele. 2 There are only a few examples of apparent SERT-related dysfunction in the periphery. Nevertheless, serotonin plays an important role outside the central nervous system, particularly in sustaining gastrointestinal function. 3 Two studies found significantly greater risk for myocardial infarction in individuals with the LL genotype. 4, 5 The latter findings remain unexplained. The Vienna Transdanube Aging (VITA) study investigates an age cohort (mean age 75.7 years, s.d. = 0.45 years) of all inhabitants of a defined geographical area in Vienna, Austria. 6 Six hundred and ninety-seven out of 1505 inhabitants of this age participated; blood could be investigated in 606 participants and 5HTTLPR could be examined in 566 individuals ( Table 1) .
The 5HTTLPR genotype distribution in the VITA population is 36% LL, 48% SL and 16% SS, which does not deviate from Hardy-Weinberg equilibrium (w 2 = 0.0281, P = 0.986). Mean fasting LDL-cholesterol levels (mg/dl) were higher in individuals with the L-allele than in individuals with the S-allele (Table 1) Data from this epidemiological study replicated the finding of an association between artherosclerosis events and the LL genotype of 5HTTLPR. Our analyses further detected that 5HTTLPR influences LDL-cholesterol levels, especially in women. The L-allele was associated with higher LDL-cholesterol, and the S-allele with lower LDL-cholesterol. In case of replication, this finding will induce a great deal of research on the serotonergic influence on LDL-cholesterol. Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein. a ANOVA, df = 558, F = 6.44, P = 0.002; level of significance P = 0.006 (Bonferroni corrected).
Letters to the Editor
Autism spectrum disorder (ASD) is conceptualized as a spectrum of related diagnostic categories, comprising subtypes: autism, atypical autism, Asperger's syndrome and other pervasive developmental disorders (ICD-10). Available evidence suggests that several genes contribute to the underlying genetic risk for the development of ASD. However, etiologic and phenotypic heterogeneity impede the discovery of ASDsusceptibility genes. We tested 148 simplex UK families, characterized by both ADI-R and ADOS to have an autism spectrum disorder (ASD), for association with candidate genes, GABRB3, GABRG3, UBE3A and ATP10C, on chromosome 15q11-13. A dense map of single nucleotide polymorphisms (SNPs) that had not been previously parsed in autism, spaced on average by 13 kb, were genotyped across each gene. We found evidence for an association with GABRB3 and ASD. A haplotype analysis of five adjacent SNPs in high linkage disequilibrium (LD) on GABRB3 was significant with a Bonferronicorrected P-value of 0.00013 for haplotypes of frequency > 1% (99.9% of all possible haplotypes covered were represented by seven haplotypes).
Further systematic examination of GABRB3 in relation to ASD is required. Chromosome 15q11-q13 (the Prader-Willi/Angelman Critical Region -PWACR) has been identified as a strong candidate region. 1 Evidence for this comes from reports that autistic symptoms are common in patients with chromosomal abnormalities of this region, especially if there is duplications of the maternally derived chromosome 15, as outlined in Bolton et al. 2 There have also been a number of suggestive linkage findings. [3] [4] [5] [6] [7] Our group had marginally suggestive results from an association analysis of ASD with five microsatellite markers spread across the PWACR. 8 Furthermore, association studies have found evidence implicating candidate genes in the region. GABRB3, composed of nine exons spanning 250 kb, is thought probably not to be imprinted. Several reports have documented findings of allelic association at microsatellite markers near/in the gene GABRB3; 155CA-2 9,10 and GABRB3 11 and more recently a dense set of single nucleotide polymorphism (SNP) markers on GABRB3 found nominal significance for association with five SNPs across the gene.
12 GABRG3 has been reported to be associated with ASD.
13 A recent detailed examination of GABA receptor genes in autism found evidence for some of these GABA receptor gene subtypes to be involved in aetiology, perhaps involving complex gene-gene interactions between the subtypes.
14 However, none of the GABA genes in the 15q11-13 region were found to be associated with autism in that study.
Evidence to support a role for the GABA neurotransmitter system in autism susceptibility include; (a) reduced binding of radiolabeled GABA A receptor ligands in autopsy brain specimens from individuals with autism, 15 (b) elevated levels of circulating GABA and its essential precursor glutamate have been observed in children with autism 16 and (c) during development it is known to have neurotrophic effects. 17 Furthermore, there is evidence to suggest that disruption of GABAergic interneuron development may represent a common point of convergence underlying the etiologies of developmental disorders including autism.
18 Also, we reported in vivo, using magnetic resonance imaging (MRS), that people with ASD have increased levels of the GABA precursors glutamate/glutamine in the amygdala-hippocampal complex (a brain region crucial to social communication (Page et al., in press 19 ). UBE3A encodes a member of a family of functionally related proteins important in ubiquitin transfer and is maternally expressed in brain with cell and region specificity. 20 Markers in UBE3A have also been reported to be associated with autism 6 and a mixed epigenetic/genetic model for oligogenic inheritance of autism with a limited role for UBE3A has been proposed.
21 ATP10C is a probable calcium-transporting ATPase with wide expression including the brain. Meguro et al. 22 reported that the ATP10C gene is maternally expressed, that it maps within the most common interval of deletion responsible for Angelman syndrome (15q11-q13), and that ATP10C expression is virtually absent from Angelman syndrome patients with imprinting mutations, as well as from patients with maternal deletions of 15q11-q13.
